Friday, 18 Jan 2019

You are here

The RheumNow Week in Review – 12 May 2017

Dr. Jack Cush highlights the big stories, news and articles from this week at

  1. Prevalence of PsA is increasing in Denmark (7.3 in 1997 to 27.3/100k PY 2010), higher in women, ages 50-59yrs,  also more DMARD and biologic use
  2. Minocycline can be a potential Rx option for Calcinosis related digital ulcers in Scleroderma.
  3. CAMERA Study: tis better to add 10mg pred to MTX than not: less Biologic use (30vs50%), less erosions, same safety
  4. World Lupus Day was 5/10 - Lupus must be managed as one person, one disease; not as a patient wth 4 organ systems affected, each requiring  a specialist to weigh in
  5. Stroke is uncommon in RA 3.2/1000 PY;3 fold higher after a serious adverse event.  Risks higher with age, smoking hyperlipidemia and H. Zoster!
  6. Adalimumab Effective in Pediatric Plaque Psoriasis  
  7. 2017 Medscape review shows Avg Rheumatologist Salary = $235K, 25%  have a networth >$2million, 17% paying school loans, 11% claim financial losses from practice
  8. EUSTAR Study: Scleroderma patients with anti-RNA polymerase III Abs have higher risk of cancer (OR 7.38), especially with higher  age & more skin involvement.
  9. ACP Guideline Recommends Generic Bisphosphonates But Limits DEXA Use
  10. NSAIDs Increase Risk of Acute Myocardial Infarction  
  11. CDC Shows a 40% Lifetime Risk of Symptomatic Hand Osteoarthritis
  12. OARSI has submitted 103pg white paper to FDA declaring OA is a "serious dz with no current satisfactory treatments"
  13. HUMOR Study - Humira shown to have no effect in hand OA. 43pt crossover RCT #OARSI mtg.


The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

I can't help but wonder if the reported increase in heart disease associated with active RA is really due to increased inflammation affecting plaque formation or the effects of NSAIDs that have been widely used in the past as background therapy for DMARDs. Another condition for whuch we have little therapy and is possibly related to inflammatory OA is CPPD disease. All we really have is steroids for pseudogout even though colchicine and DMARDs are used in desperation, not to mention Plaquenil. I appreciate your concise reports.
David, thanks for the thoughts. OA needs a big push from all of us. RA and CVD I believe is largely driven by both inflammation and preclinical pathology that may be related to ACPA and other factors we link with bad RA, those just happen to be proatherogenic too! - Jack

More Like This

RheumNow Podcast – FDA Panels Meet on Gout & OP (1.18.19)

Dr Jack Cush Reviews the news, articles and FDA Panel discussions from the past week

Assessing the Performance of Aging Physicians

A JAMA Viewpoint article examines the performance of aging surgeons and notes that the effects of aging affects physicians variably and that physician competency should be based on functional age (and abilities) rather than chronologic age. This argues against a mandatory retirement age for surgeons.

RheumNow Podcast – Gout Spot Light (1.11.19)

Dr. Jack Cush discusses the highlights from the past week on

RheumNow Podcast – A Grand New Year (1.4.19)

Dr. Jack Cush reviews the news and journals for the beginning of 2019. All from Best wishes for a charmed 2019! My advice: 1. Just show up. 2. If you can, then you must do. 3. Live each day as if it twas your 1st day/last day/make or break day. 4. Teach.

Best of 2018: U.S. News 2018-19 Rheumatology Rankings

The Annual U.S. News and World Report Rankings of Hospitals has listed the top contenders in the field of rheumatology. The U.S. News Review rates hospitals nationwide in 16 specialties – including rheumatology. Of the 4,500 hospitals covered by U.S. News that were analyzed, 158 were classified nationally in at least one specialty area.